Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
暂无分享，去创建一个
J. Dipersio | H. Kantarjian | J. Cortes | G. Saglio | H. Khoury | D. Healey | O. Ottmann | Dong-Wook Kim | J. Apperley | C. Arthur | A. Charbonnier | E. Bullorsky | L. Strauss
[1] H. Kantarjian,et al. Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034 , 2016, American journal of hematology.
[2] J. Radich. Major progress in understanding progression in chronic myeloid leukemia , 2015, The Journal of experimental medicine.
[3] M. Konopleva,et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. , 2015, The Lancet. Haematology.
[4] H. Kantarjian,et al. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. , 2014, Clinical lymphoma, myeloma & leukemia.
[5] J. Cayuela,et al. First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia , 2012, Leukemia.
[6] Martin C. Müller,et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. , 2009, Blood.
[7] N. Tuzuner,et al. Cytogenetic Clonal Evolution in Patients with Chronic Myeloid Leukemia , 2009 .
[8] J. Dipersio,et al. Dasatinib 140 mg QD compared to 70 mg BID in advanced-phase CML or Ph(+) ALL resistant or intolerant to imatinib: One-year results of CA180–035 , 2007 .